Viewing Study NCT00004334


Ignite Creation Date: 2025-12-25 @ 2:30 AM
Ignite Modification Date: 2025-12-30 @ 8:23 AM
Study NCT ID: NCT00004334
Status: UNKNOWN
Last Update Posted: 2005-06-24
First Post: 1999-10-18
Is Gene Therapy: True
Has Adverse Events: False

Brief Title: Study of Depression, Peptides, and Steroids in Cushing's Syndrome
Sponsor: National Center for Research Resources (NCRR)
Organization:

Study Overview

Official Title: None
Status: UNKNOWN
Status Verified Date: 2003-12
Last Known Status: RECRUITING
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: OBJECTIVES: I. Study the relationship between dysregulation of the hypothalamic-pituitary-adrenal (HPA) axis and disorders of mood, vegetative function, and cognition in patients with Cushing's disease.

II. Identify subgroups of patients with Cushing's disease who differ in the presence and severity of the depressive syndrome, and uncover HPA axis dysregulation differences among them using corticotropin-releasing hormone, metyrapone, and dexamethasone challenge testing.
Detailed Description: PROTOCOL OUTLINE: All patients receive a psychiatric evaluation at baseline, as well as assessments of plasma adrenocorticotropin, beta lipotropin, beta endorphin, and cortisol, and urinary cortisol. Peptide and steroid assays are performed, alone and in response to corticotropin-releasing hormone, metyrapone, and dexamethasone. Patients are given sleep electroencephalograms at baseline and 1 year following treatment.

A weight maintenance diet is prescribed for all patients.

Study Oversight

Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?:

Secondary ID Infos

Secondary ID Type Domain Link View
UMMC-701 None None View